SCIENTIFIC CULTURE
www.sci-cult.com

SCIENTIFIC CULTURE, Vol. 12, No. 5.1, (2026), pp. 124-131
Open Access. Online & Print

DOI: 10.5281/zenodo.12511011

COMMUNITY HEALTH NURSING STRATEGIES FOR MANAGING GESTATIONAL DIABETES MELLITUS: ENHANCING MATERNAL AND NEONATAL OUTCOMES THROUGH EVIDENCE-BASED CARE

Ahmad Mahmoud Saleh, Ph.D [1*], Amira Abd El-azeem Mohamed Yossif, Ph.D [2], Wafaa Mohamed Amer Mahmoud, Ph.D [3], Wafaa Mohamed Elsayed Ahmed, Ph.D.[4], Sabah Ahmed Ammar Mohamed, Ph.D

[1 2 3]Nursing College, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
[4]Faculty of Nursing, Al Ryada University for Science and Technology, Egypt.
[5]Nursing College, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia. Faculty of Nursing, Helwan University, Cairo, Egypt

Received: 11/12/2024
Accepted: 25/02/2025

Corresponding author: Ahmad Mahmoud Saleh, Ph.D
(am.saleh@psau.edu.sa)

ABSTRACT

This literature review explored the impact of GDM on maternal and fetal health and examined current approaches to its management. A literature search from 2017 to 2023 was conducted using the keywords "Gestational Diabetes Mellitus," "persistent hyperglycemia," "chronic insulin resistance," "long-term management," "comprehensive approaches," and "pancreatic beta cell failure." There is no universally recognized preventive or treatment plan for GDM. Current strategies emphasize lifestyle modification, while insulin therapy and oral agents such as metformin and glyburide show limited or uncertain long-term safety. Addressing research gaps through multidisciplinary approaches can enhance prevention and management of GDM. This aligns with the United Nations Sustainable Development Goals (SDG 3: Good Health and Well-Being and SDG 5: Gender Equality) by promoting maternal health, reducing neonatal complications, and empowering women through equitable access to quality healthcare

KEYWORDS: Gestational Diabetes Mellitus; Maternal Health; Insulin Resistance; Sustainable Development Goals; SDG 3 – Good Health.

1. INTRODUCTION

Gestational diabetes mellitus (GDM) is a temporary metabolic disorder that develops during pregnancy in previously non-diabetic women and is defined by high blood glucose levels 1,2. GDM is a condition that affects around 9% of pregnancies globally 3. It is often detected between weeks 24 and 28 of gestation, and its frequency is rising as a result of variables including rising maternal weight, advancing maternal age, and sedentary lifestyle 4

The primary cause of gestational diabetes mellitus is the incapacity of the mother's pancreas to adjust to the increased demands for insulin during pregnancy. Insulin responsiveness declines during pregnancy, which causes pancreatic beta cells to produce more insulin 5. Insulin is essential for controlling adipose tissue lipid release, hepatic glucose production decrease, and peripheral tissue absorption of glucose 6,7. Insulin resistance is caused by insufficient insulin receptor responsiveness, which forces beta cells to produce more insulin to keep high blood glucose levels within normal ranges. Placental hormones regulate this insulin resistance for embryonic feeding, which in turn triggers adaptive responses in beta cells. But when these adjustments break down, GDM sets up, which causes hyperglycemia 8.

Pregnancy-related GDM detection and therapy are essential because of the possibility of short-term problems such as elevated blood pressure, the need for a Cesarean section, pre-eclampsia, and difficult deliveries 8. The recurrence of GDM in consecutive pregnancies increases the long-term risk of type 2 diabetes in the mother 9. GDM treatment has been the subject of recent research projects, including glycemic control strategies. Although earlier research on the effect of probiotics on the course of GDM produced conflicting findings, modern therapeutic approaches try to reduce risks for both mother and child by controlling blood sugar levels 9.

Patients with GDM need to learn all there is to know about the disease to maximize blood sugar management . The major therapy approaches are lifestyle changes that include eating differently, exercising often, and maintaining a healthy weight. If lifestyle modifications are not enough to decrease blood sugar levels, medications such as insulin, metformin, Glibenclamide, and glucose-lowering medicines may be taken into consideration 10. After giving birth, it is recommended to stop using GDM medicines since insulin sensitivity returns quickly. This overview of the literature summarizes what is already known while highlighting the need for further study to improve GDM management techniques.

2. LITERATURE REVIEW

Impacts of Gestational Diabetes Mellitus on Maternal Health

Due to its significant short- and long-term impact on maternal health, gestational diabetes mellitus (GDM) deserves in-depth investigation in the literature. Prenatal depression has been linked to gestational diabetes mellitus (GDM), in addition to the usual difficulties of a typical pregnancy 11. Surgical delivery is often required due to the increased risk of difficulties in future pregnancies, such as hypertension and premature birth. In addition, women with GDM have a markedly increased risk of acquiring diabetes mellitus in the future 11.

After Delivery, 10% of women with GDM are diagnosed with postpartum diabetes mellitus; if targeted therapies are not provided, up to 60% of these women may acquire the illness within 5–10 years following the index pregnancy 12. Although not every woman with gestational diabetes goes on to develop diabetes mellitus, a significant majority do, according to long-term statistics currently available 13. Although higher, the risk of postpartum diabetes mellitus is still less than the chance of women getting diabetes mellitus after being diagnosed with gestational diabetes mellitus 14. This raises the possibility that GDM, like non-pregnant persons with glucose intolerance, is a prelude to diabetes12.

A significant portion of post-GDM diabetes patients fit the description of pre-Type 2 Diabetes Mellitus (T2DM). Studies show that beta cell compensation for insulin resistance decreases with time, highlighting the chronic character of this metabolic condition 14. The fast development of diabetes mellitus after delivery is associated with risk factors, including higher glucose levels, insulin resistance, and reduced beta cell function. After their health deteriorates, women with these characteristics may exceed the glucose levels that indicate diabetes mellitus 14.

Weight increase, insulin resistance, increasing C-reactive protein levels, and decreasing adiponectin levels are among the factors that contribute to beta cell degeneration 15. The metabolic effects of obesity are crucial in the degradation of beta cells and the eventual onset of diabetes mellitus 16. Reducing obesity with diet, exercise, or drugs that improve the function and composition of adipose tissue is a good way to effectively reduce the risk 16.

The basis for the development of Type 2 Diabetes Mellitus is metabolic syndrome, which includes obesity and related conditions. Compared to women without GDM, individuals with GDM are more likely to show signs of metabolic syndrome 1. Furthermore, there is a noteworthy correlation between the frequency of cardiovascular risk factors and incidents and prior bouts of GDM 17. Notably, a significant percentage of obese people also have GDM, and maternal obesity is common among GDM patients 13. The results of a meta-analysis highlight the increased risk of gestational diabetes mellitus (GDM) diagnosis among pregnant women who are overweight, obese, or severely obese 10,12,17. This highlights the complex relationship between maternal health, GDM, and long-term metabolic consequences 18.

2.1. Challenges and Risks: Navigating Complications in Pregnancy

The difficulties involved in giving birth vaginally are markedly increased when the baby is macrosomic 19. It is important to give considerable thought to the possibility of a lengthy labor phase in which the fetus gets trapped in the delivery canal 19. It may become necessary to do instrumental births using forceps or vacuum extraction, or an unplanned emergency cesarean section may be necessary 15. Compared to delivery of babies of normal size, there is a markedly increased risk of perineal tears, which include ripping of the muscles between the vagina and the anus, as well as lacerations and rips of the vaginal tissue 14.

Furthermore, there is significant worry about the possibility of uterine atony, which is defined as the inability of the uterine muscle to contract properly 12,20. Postpartum hemorrhage and severe bleeding may result from this failure 21. There is a three- to five-fold increased risk of genital tract injury and postpartum bleeding in macrosomic newborns . It should be noted that women who have had past cesarean sections are more likely to have uterine ripping along the surgical scar tissue from that treatment. These results highlight the complex factors and possible issues related to macrosomic deliveries in the framework of a literature review, offering insightful information to academics and physicians alike 21.

2.2. Fetal complications and effects

2.2.1. Premature Birth

A premature birth puts an infant at serious risk for complications like respiratory and feeding issues, infections, jaundice, admission to the neonatal intensive care unit (NICU), and perinatal mortality 22. Premature birth is defined as the induction of labor before 39 weeks gestation and the early rupture of membranes . The rate of preterm birth is still about 10.6% worldwide even with significant efforts to control early labor; this is especially true when combined with other risks including maternal obesity and hypertension during pregnancy 23. The goal of this review of the literature is to shed light on the difficulties and current knowledge of this common problem by examining the complex characteristics of preterm delivery and the issues that are connected with it.

2.2.2. Hypoglycemia at Birth

In addition to hurting the health of the mother, gestational diabetes mellitus (GDM) also hurts the growing fetus 1. Limited fetal glucose synthesis occurs, mostly from the blood of the mother. Contrary to maternal insulin, glucose crosses the placenta 24. According to a modified version of Pedersen's idea, extra glucose carried across the placenta by raised and uncontrolled maternal glucose levels causes greater fetal insulin production. Increased expression of glucose transport proteins (GLUTs) in pregnancies with insulin-dependent diabetes mellitus is indicative of this condition. Moreover, insulin leads to increased placental mTOR activity. Insulin is well-known for its function in triggering mTOR, a powerful regulator of cell proliferation 25.

Elevated maternal insulin stimulates the placental system A and system L amino acid transporters, which in turn promote cell division and provide vital nutrients to the growing baby. As a result, hyperglycemia and hyperinsulinemia in mothers might cause fetal changes similar to those seen in GDM, which may result in newborn obesity 26. Excessive nutrition storage, especially in the fetal belly and shoulders, is the cause of macrosomia, a condition marked by an increase in neonatal size at delivery. Between 15% and 45% of fetuses with GDM have macrosomia . Furthermore, a higher prevalence of respiratory distress in neonates is linked to GDM 27. Examining the complex processes that connect gestational diabetes mellitus (GDM) to fetal outcomes, this study focuses on how GDM affects newborn size, metabolism, and respiratory function.

2.2.3. Shoulder Dystocia and Erb's Palsy

One major issue related to birth trauma is shoulder dystocia, which is a serious consequence of vaginal delivery that should be taken seriously, especially when it comes to macrosomic babies. Compared to infants with lower birth weights, those who weigh 4,500 g or more are six times more likely to experience delivery stress 28. Furthermore, there is a roughly twentyfold increased risk of brachial plexus injury when the birth weight is greater than 4,500 g 28. The complex association between shoulder dystocia, delivery trauma, and macrosomic newborns is examined in this research review, which also discusses the consequences for neonatal health and the increased risks associated with greater birth weights.

2.2.4. Congenital Anomalies

Neural tube abnormalities including spina bifida and congenital cardiac problems are among the most common newborn issues. The development of the fetus's organs has been linked to high blood sugar levels in women with Gestational Diabetes Mellitus (GDM), which may add to congenital defects 29. Nevertheless, the exact nature of the correlation between GDM and fetal malformations is still unknown, since this interaction is characterized by contradictory results. By contrast, there is a strong association that shows a twofold greater frequency of congenital anomalies in women with pre-existing diabetes than in non-diabetic persons. To better understand the intricate interactions between maternal glucose levels, gestational diabetes, and unfavorable fetal outcomes, further study is necessary, as this literature review emphasizes.

2.2.5. Fetal Nutrition

When gestational diabetes mellitus (GDM) develops, there are noticeable alterations to the makeup of breast milk 30. Breast milk is a constantly developing fluid with bioactivity that varies greatly across people and during the lactation cycle. Several maternal variables might affect breast milk. These include illnesses, maternal nutrition, metabolic disorders, and both term and preterm labor. Diabetes mellitus, which is defined as a chronic metabolic disease, may affect expecting moms either before or after becoming pregnant, creating a unique condition 31.

Particular changes in the content of breast milk become apparent in the setting of GDM. The normalization of citrate, lactose, and total nitrogen levels is delayed in mothers with gestational diabetes; it takes an extra 15 to 24 hours for these mothers' values to resemble those of healthy women 30. The positive relationship between the formation of the mammary glands during pregnancy and the amount of human placental lactogen in the blood is thought to be the cause of this delay.

Elevated cytokine and chemokine levels in the colostrum of pregnant women with gestational diabetes mellitus indicate a changed immunological makeup. Notably, there is an increase in interleukin (IL)-6, IL-15, and interferon-γ, but a reduction in IL-1ra and granulocyte-macrophage colony-stimulating factor (GM-CSF) 32.

2.2.6. Neonatal complications

Neonatal complications include a wide range of difficulties, from possible problems such as hypoxia, hypoglycemia, kernicterus, and jaundice, to birth trauma, such as shoulder dystocia and brachial plexus injuries. Newborn respiratory distress syndrome (NRDS) and bacterial infections are further potential risks for infants 33. The variety of health issues that might surface in an infant's early years is highlighted by this range of difficulties.

2.2.7. Neonatal Jaundice

Prematurity, inadequate nutrition, and increased enterohepatic circulation of bilirubin due to reduced hepatic conjugation may all cause jaundice in neonates. Macrosomia newborns have higher oxygen requirements, which accelerate erythropoiesis and result in polycythemia 34. Newborn jaundice is partly caused by this increased red blood cell turnover, which raises bilirubin levels, a byproduct of red blood cell breakdown 34

2.2.8. Childhood and adulthood complications

Seminal research has established a link between hyperglycemia in offspring and Gestational Diabetes Mellitus (GDM) 35. Research conducted among Pima Indians in the USA has provided concrete evidence that offspring hyperglycemia may be associated with the development of adult-onset diseases in adulthood 35,36. Children born to moms with diabetes have a higher chance of developing obesity, hypertension, and dyslipidemia as adults 36. An additional link between maternal hyperglycemia during pregnancy and elevated hyperglycemia and insulin resistance in developing children was found by the global Hyperglycemia and Adverse Pregnancy Outcome (HAPO) research, which was conducted across ten nations 37.

The offspring of mothers with GDM had higher values for body mass index (BMI), waist measures, triglyceride levels, and the homeostatic model assessment of insulin resistance (HOMA-IR) when compared to those whose mothers had normal blood sugar levels. The effects of GDM exposure during pregnancy and childhood continue throughout adolescence; by the time they are 22 years old, 20% of GDM children have type 2 diabetes and prediabetes, highlighting the possible involvement of insulin resistance in the development of illness 38.

Apart from the heightened risk of obesity, offspring of GDM moms are linked to heightened cardiovascular risk, adiposity, and an increased probability of cardiac arrhythmias, which may cause hospitalization for cardiovascular disorders (CVDs). Moreover, children with GDM have a 29% higher chance of developing early-onset cardiovascular diseases, such as pulmonary embolism, deep vein thrombosis, hypertension, and heart failure 39.

Collectively, these results highlight the crucial role that the in-utero environment plays in programming metabolic disorders in children, and population studies indicate that childhood experiences are likely to carry over into adulthood. It's important to remember that adolescence is a particularly sensitive time for the development of obesity and related health issues and that exposure to GDM during pregnancy may have long-term effects that appear at this time. This review of the literature explores the wealth of studies that clarify the profound effects of GDM on the health of children throughout the life cycle.

2.3. Navigating Treatment Options

For those with Gestational Diabetes Mellitus (GDM), the best course of treatment necessitates a multifaceted approach that includes blood sugar control, dietary modifications, weight growth throughout pregnancy, and patient education 40. In 70%–85% of instances with GDM, lifestyle adjustments like exercise and nutrition may be curative ; in 15%–30% of cases, medication such as insulin or oral hypoglycemic may be necessary 41.

One of the most important parts of managing GDM is blood glucose monitoring, with most organizations recommending daily at-home self-glucose monitoring. The American Diabetes Association (ADA) recommends monitoring blood glucose levels after meals and during fasting, with goal values of 95 mg/dL for fasting and 140 mg/dL or 120 mg/dL one to two hours after a meal. On the other hand, Haemoglobin A1C screening is less useful for assessing glucose control in GDM, and pre-prandial glucose monitoring is more advantageous for those with pre-existing diabetes 42.

Several techniques, including the DASH diet, calorie-restricted diets, low-glycemic index diets, low-carb diets, low-unsaturated fat diets, high-fiber diets, and soy-based diets, have been investigated in the literature as important dietary adjustments 43. It is advised to place a focus on eating a balanced diet that includes appropriate serving sizes, healthy fats, complex carbohydrates, and enough protein.

Even pregnant women with gestational diabetes mellitus (GDM) are encouraged to engage in regular physical activity and exercise since it may reduce the risk of gestational diabetes, increase the chance of larger-than-normal babies, and lower the risk of high blood pressure issues, preterm delivery, and fetal growth limitation. Postpartum depression risk is decreased by these lifestyle changes, which continue throughout the postpartum phase 44.

For 15% to 30% of GDM patients, medication is required if blood glucose control is still insufficient after lifestyle modifications 45. To manage hyperglycemia, insulin and oral drugs such as glyburide and metformin are used. Because insulin cannot cross the placenta, it is seen to be the safest choice during pregnancy. Though studied and used, metformin and glyburide have been shown to cross the placental barrier and reach the fetus 45.

Table 1: Methodological Characteristics of the Reviewed Studies

Author	Year	Findings
Alejandro et al. 46	2020	This study highlights the gravity of GDM and the issues surrounding its management, including identifying and managing risk factors, receiving an accurate diagnosis, and treating the illness to prevent related side effects.
Damm et al. 47	2016	Most communities are seeing an increase in GDM cases, and there is strong evidence that this condition is a factor in the worldwide diabetes pandemic.
Moon et al. 48	2022	Two to three times as many women were diagnosed with GDM using the one-step technique as with the two-step approach.
Billionnet et al. 49	2012	Insulin-treated GDM has a higher chance of most outcomes than non-insulin-treated GDM, and GDM is linked to a considerably increased risk of poor neonatal outcomes.
Byrn et al. 50	2015	The results show that depression symptoms are common in the prepartum phase, which emphasizes the need of screening and education about this condition. Another indicator of impending GDM development might be a past history of depression.
Buchanan et al. 51	2012	There is a considerable variance in GDM, even among the great majority of women who do not have autoimmunity or monogenic diabetes.
Metzger et al 52	2010	Internationally accepted recommendations for the diagnosis and categorization of diabetes during pregnancy by diabetes, obstetrics, and other organizations may be based on this publication.
Xiang et al. 53	2010	Within 12 years after the index pregnancy, type 2 diabetes is most likely to strike women who decline the quickest and/or are most behind schedule for diagnosis.

3. CONCLUSIONS

The most common metabolic disease during pregnancy, gestational diabetes mellitus, (GDM), still has a major detrimental impact on world health. An increased risk of gestational hypertension, cesarean sections, and other fetal-related problems are among the immediate impacts. An increased risk of type 2 diabetes after birth is one of the long-term repercussions of gestational diabetes mellitus (GDM), which emphasizes the importance of continued monitoring and treatment for afflicted moms. Furthermore, the effect that GDM has on offspring is a very serious matter. This research highlights the increased risk of obesity, hypertension, and insulin resistance in kids of women with gestational diabetes mellitus, conditions that may persist into adulthood. Understanding these implications for intergenerational health is crucial for proactive treatment and prevention.

Treating GDM effectively requires a multimodal approach. Close blood glucose monitoring, dietary modifications, regular exercise, and, if necessary, prescription treatments are all part of this plan. By collaborating and focusing on personalized care and education, healthcare professionals and expectant mothers may successfully manage gestational diabetes mellitus. A qualified dietitian should provide dietary advice to all women with GDM since this is the cornerstone of GDM treatment. Although there have been tremendous advancements in GDM research and treatment, disparities in recommended therapies still exist. Furthermore, a variety of treatment alternatives for GDM are being investigated, even though the data at this time does not support the long-term effectiveness of these approaches. Furthermore, an integrated approach that includes intense health education, population-wide preventive management, early identification, and multidisciplinary treatment programs should be reinforced to prevent and control GDM. This strategy may help long-term health, enhance the outcomes of pregnancies for moms and babies, and reduce the risk of GDM and associated consequences in both high-risk and general populations

REFERENCES

1. Abbey, P., Kandasamy, D., & Naranje, P. (2019). Neonatal jaundice. The Indian Journal of Pediatrics, 86, 830–841.
2. Agosti, M., Tandoi, F., Morlacchi, L., & Bossi, A. (2017). Nutritional and metabolic programming during the first thousand days of life. La Pediatria Medica e Chirurgica, 39(2).
3. Akhaphong, B., Baumann, D. C., Beetch, M., Lockridge, A. D., Jo, S., Wong, A., Zemanovic, T., Mohan, R., Fondevilla, D. L., & Sia, M. (2021). Placental mTOR complex 1 regulates fetal programming of obesity and insulin resistance in mice. JCI Insight, 6(13).
4. Alejandro, E. U., Mamerto, T. P., Chung, G., Villavieja, A., Gaus, N. L., Morgan, E., & Pineda-Cortel, M. R. B. (2020). Gestational diabetes mellitus: a harbinger of the vicious cycle of diabetes. International Journal of Molecular Sciences, 21(14), 5003.
5. Auger, N., Arbour, L., Schnitzer, M. E., Healy-Profitós, J., Nadeau, G., & Fraser, W. D. (2019). Pregnancy outcomes of women with spina bifida. Disability and Rehabilitation, 41(12), 1403–1409.
6. Basher, R. H., Hussien, M. S., & Nessr, N. B. (2019). Maternal and neonatal complications in macrosomic pregnancies. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 8(8), 3147–3152.
7. Bianco, M. E., Kuang, A., Josefson, J. L., Catalano, P. M., Dyer, A. R., Lowe, L. P., Metzger, B. E., Scholtens, D. M., Lowe, W. L., & Group, H. F.-U. S. C. R. (2021). Hyperglycemia and adverse pregnancy outcome follow-up study: newborn anthropometrics and childhood glucose metabolism. Diabetologia, 64, 561–570.
8. Billionnet, C., Mitanchez, D., Weill, A., Nizard, J., Alla, F., Hartemann, A., & Jacqueminet, S. (2017). Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia, 60, 636–644.
9. Buchanan, T. A., Xiang, A. H., & Page, K. A. (2012). Gestational diabetes mellitus: risks and management during and after pregnancy. Nature Reviews Endocrinology, 8(11), 639.
10. Byrn, M., & Penckofer, S. (2015). The relationship between gestational diabetes and antenatal depression. Journal of Obstetric, Gynecologic & Neonatal Nursing, 44(2), 246–255.
11. Cai, D., & Yan, S. (2024). Ultrasonographic diagnosis of fetal hemodynamic parameters in pregnant women with diabetes mellitus in the third trimester of pregnancy. Heliyon.
12. Cao, G., Liu, J., & Liu, M. (2022). Global, regional, and national incidence and mortality of neonatal preterm birth, 1990-2019. JAMA Pediatrics, 176(8), 787–796.
13. Chebrolu, P., Kurbude, R., Thakur, M., Shah, N., & Jain, R. (2021). Gestational diabetes in rural central India: low prevalence but absence of typical risk factors. Heliyon, 7(7).
14. Choudhury, A. A., & Rajeswari, V. D. (2021). Gestational diabetes mellitus-A metabolic and

reproductive disorder. Biomedicine & Pharmacotherapy, 143, 112183.

15. Cnattingius, S., Källén, K., Sandström, A., Rydberg, H., Månsson, H., Stephansson, O., Frisell, T., & Ludvigsson, J. F. (2023). The Swedish medical birth register during five decades: documentation of the content and quality of the register. European Journal of Epidemiology, 38(1), 109–120.
16. Coetzee, A., Mason, D., Hall, D. R., & Conradie, M. (2018). Prevalence and predictive factors of early postpartum diabetes among women with gestational diabetes in a single-center cohort. International Journal of Gynecology & Obstetrics, 142(1), 54–60.
17. Damm, P., Houshmand-Oeregaard, A., Kelstrup, L., Lauenborg, J., Mathiesen, E. R., & Clausen, T. D. (2016). Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Diabetologia, 59, 1396–1399.
18. Di, J., Jia, M., Zhou, Y., Zhu, Q., Wu, L., & Liu, J. (2024). Motivational factors for dietary intake behavior in gestational diabetes mellitus: a cross-sectional study. Heliyon.
19. Dirar, A. M., & Doupis, J. (2017). Gestational diabetes from A to Z. World Journal of Diabetes, 8(12), 489.
20. Fan, X., Wang, L., Jiao, R., Song, W., Liu, Y., & Yu, T. (2023). Correlation between high serum ferritin levels and adverse pregnancy outcomes in women with gestational diabetes mellitus. Heliyon, 9(3).
21. Farahvar, S., Walfisch, A., & Sheiner, E. (2019). Gestational diabetes risk factors and long-term consequences for both mother and offspring: a literature review. Expert Review of Endocrinology & Metabolism, 14(1), 63–74.
22. Feingold, K. R. (2022). Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext [Internet].
23. Ghaedrahmati, M., Kazemi, A., Kheirabadi, G., Ebrahimi, A., & Bahrami, M. (2017). Postpartum depression risk factors: A narrative review. Journal of Education and Health Promotion, 6.
24. Gyasi-Antwi, P., Walker, L., Moody, C., Okyere, S., Salt, K., Anang, L., Eduful, E., Laryea, D., Ottie-Boakye, D., & Asah-Opoku, K. (2020). Global prevalence of gestational diabetes mellitus: a systematic review and meta-analysis. New American Journal of Medicine, 1(3).
25. Howlader, M., Sultana, M. I., Akter, F., & Hossain, M. M. (2021). Adiponectin gene polymorphisms associated with diabetes mellitus: A descriptive review. Heliyon, 7(8).
26. Hudish, L. I., Reusch, J. E. B., & Sussel, L. (2019). β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. The Journal of Clinical Investigation, 129(10), 4001–4008.
27. Jones, L. V, Ray, A., Moy, F. M., & Buckley, B. S. (2019). Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes. Cochrane Database of Systematic Reviews, 5.
28. Lee, S. Bin, Jung, S. H., Lee, H., Lee, S. M., Jung, J. E., Kim, N., & Lee, J. Y. (2023). Maternal vitamin D deficiency in early pregnancy and perinatal and long-term outcomes. Heliyon, 9(9).
29. Metzger, B. E., Gabbe, S. G., Persson, B., Lowe, L. P., Dyer, A. R., Oats, J. J. N., & Buchanan, T. A. (2010). International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy: response to Weinert. Diabetes Care, 33(7), e98–e98.
30. Minschart, C., De Weerdt, K., Elegeert, A., Van Crombrugge, P., Moyson, C., Verhaeghe, J., Vandeginste, S., Verlaenen, H., Vercammen, C., & Maes, T. (2021). Antenatal depression and risk of gestational diabetes, adverse pregnancy outcomes, and postpartum quality of life. The Journal of Clinical Endocrinology & Metabolism, 106(8), e3110–e3124.
31. Moon, J. H., & Jang, H. C. (2022). Gestational diabetes mellitus: diagnostic approaches and maternal-offspring complications. Diabetes & Metabolism Journal, 46(1), 3–14.
32. Mortier, I., Blanc, J., Tosello, B., Gire, C., Bretelle, F., & Carcopino, X. (2017). Is gestational diabetes an independent risk factor of neonatal severe respiratory distress syndrome after 34 weeks of gestation? A prospective study. Archives of Gynecology and Obstetrics, 296, 1071–1077.
33. Moyce, B. L., & Dolinsky, V. W. (2018). Maternal β-cell adaptations in pregnancy and placental signalling: implications for gestational diabetes. International Journal of Molecular Sciences, 19(11), 3467.
34. Mukherjee, S. M., & Dawson, A. (2022). Diabetes: how to manage gestational diabetes mellitus. Drugs in Context, 11.
35. Nakshine, V. S., & Jogdand, S. D. (2023). A Comprehensive Review of Gestational Diabetes Mellitus: Impacts on Maternal Health, Fetal Development, Childhood Outcomes, and Long-Term Treatment Strategies. Cureus, 15(10).

36. Norton, L., Shannon, C., Gastaldelli, A., & DeFronzo, R. A. (2022). Insulin: The master regulator of glucose metabolism. Metabolism, 129, 155142.
37. Pénager, C., Bardet, P., Timsit, J., & Lepercq, J. (2020). Determinants of the persistency of macrosomia and shoulder dystocia despite treatment of gestational diabetes mellitus. Heliyon, 6(4).
38. Poznyak, A. V, Khotina, V. A., Zhigmitova, E. B., Sukhorukov, V. N., Postnov, A. Y., & Orekhov, A. N. (2023). Is There a Relationship between Adverse Pregnancy Outcomes and Future Development of Atherosclerosis? Biomedicines, 11(9), 2430.
39. Ro, A., Goldberg, R. E., & Kane, J. B. (2019). Racial and ethnic patterning of low birth weight, normal birth weight, and macrosomia. Preventive Medicine, 118, 196–204.
40. Rooholahzadegan, F., Arefhosseini, S., Tutunchi, H., Badali, T., Khoshbaten, M., & Ebrahimi-Mameghani, M. (2023). The effect of DASH diet on glycemic response, meta-inflammation and serum LPS in obese patients with NAFLD: a double-blind controlled randomized clinical trial. Nutrition & Metabolism, 20(1), 1–14.
41. Shen, Y., Wang, P., Wang, L., Zhang, S., Liu, H., Li, W., Li, N., Li, W., Leng, J., & Wang, J. (2018). Gestational diabetes with diabetes and prediabetes risks: a large observational study. European Journal of Endocrinology, 179(1), 51–58.
42. Silva, C. M., Arnegard, M. E., & Maric-Bilkan, C. (2021). Dysglycemia in pregnancy and maternal/fetal outcomes. Journal of Women's Health, 30(2), 187–193.
43. Simmons, S. (2023). Neonatal Respiratory Distress Syndrome. Care Planning in Children and Young People's Nursing 2e, 159–167.
44. Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022). A clinical update on gestational diabetes mellitus. Endocrine Reviews, 43(5), 763–793.
45. Veelen, A., Erazo-Tapia, E., Oscarsson, J., & Schrauwen, P. (2021). Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment? Molecular Metabolism, 46, 101158.
46. Vernet, R., Charrier, E., Cosset, E., Fièvre, S., Tomasello, U., Grogg, J., & Mach, N. (2021). Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model. Vaccines, 9(5), 484.
47. Wang, M., Athayde, N., Padmanabhan, S., & Cheung, N. W. (2019). Causes of stillbirths in diabetic and gestational diabetes pregnancies at a NSW tertiary referral hospital. Australian and New Zealand Journal of Obstetrics and Gynaecology, 59(4), 561–566.
48. Wicklow, B., & Retnakaran, R. (2023). Gestational diabetes mellitus and its implications across the life span. Diabetes & Metabolism Journal, 47(3), 333–344.
49. Wu, Y., Yu, J., Liu, X., Wang, W., Chen, Z., Qiao, J., Liu, X., Jin, H., Li, X., & Wen, L. (2021). Gestational diabetes mellitus-associated changes in the breast milk metabolome alters the neonatal growth trajectory. Clinical Nutrition, 40(6), 4043–4054.
50. Xiang, A. H., Kjos, S. L., Takayanagi, M., Trigo, E., & Buchanan, T. A. (2010). Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. Diabetes, 59(10), 2625–2630.
51. Zaccara, T. A. (2023). Teste oral de tolerância à glicose alterado na gestação: comparação entre pacientes com diabetes gestacional e diabetes na gestação segundo os critérios da Organização Mundial da Saúde. Universidade de São Paulo.
52. Zhou, F., Ran, X., Song, F., Wu, Q., Jia, Y., Liang, Y., Chen, S., Zhang, G., Dong, J., & Wang, Y. (2024). A Stepwise Prediction and Interpretation of Gestational Diabetes Mellitus: Foster the Practical Application of Machine Learning in Clinical Decision. Heliyon.
53. Zugravu, C., Petra, A., Pietroșel, V.-A., Mihai, B.-M., Mihai, D.-A., Bohîlțea, R.-E., & Tarcea, M. (2023). Nutritional Interventions and Lifestyle Changing in Gestational Diabetes Mellitus Prevention: A Narrative Review. Sustainability, 15(2), 1069.

.